Furthermore, high mutation rates of PDCD6, MAL2, SLC25A15 and PTDSS1 were observed in BLCA patients and some genetic alteration were significantly relevant to OS and PFS. This evidence concerns the gene SLC25A15 and bladder transitional cell carcinoma.